TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32841937

Group type: EXPERIMENTAL
Intervention: Catheter ablation
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Flecainide/Verapamil
Number of subjects: 180

Group type: COMPARATOR
Intervention: Sotalol
Number of subjects: 180
Study: 33758067

Group type: EXPERIMENTAL
Intervention: Vertebroplasty
Number of subjects: 102

Group type: COMPARATOR
Intervention: Conservative management (bed rest and orthosis)
Number of subjects: 102
Study: 33590947

Group type: EXPERIMENTAL
Intervention: Self-management interventions
Number of subjects: 12
Study: 32599274

Group type: EXPERIMENTAL
Intervention: Family Nurture Intervention (FNI)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Standard Care (SC)
Number of subjects: 64
Study: 35223743

Group type: EXPERIMENTAL
Intervention: Game-based after-school program (EXP)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Regular physical education (CON)
Number of subjects: 59
Study: 33761729

Group type: EXPERIMENTAL
Intervention: EUS‐CDS with a novel antimigration metal stent
Number of subjects: 95

Group type: COMPARATOR
Intervention: ERCP with a traditional metal stent
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: EUS‐CDS
Number of subjects: 95
Study: 34890069

Group type: EXPERIMENTAL
Intervention: MSC‐NTF treatment
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study: 33561725

Group type: EXPERIMENTAL
Intervention: random noise stimulation (tRNS)
Number of subjects: 19

Group type: COMPARATOR
Intervention: anodal transcranial direct current stimulation (tDCS)
Number of subjects: 19
Study: 35876047

Group type: EXPERIMENTAL
Intervention: Vitamin B12 supplementation
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Folic acid supplementation
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 1000
Study: 34011040

Group type: EXPERIMENTAL
Intervention: Bi Qi Capsules (BQC) in combination with Methotrexate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (Methotrexate only)
Number of subjects: 0
Study: 32403934

Group type: EXPERIMENTAL
Intervention: Pentraxin 3 (PTX3)
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Interleukin 6 (IL-6)
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: High-sensitive C-reactive protein (hs-CRP)
Number of subjects: 161
Study: 35034763

Group type: EXPERIMENTAL
Intervention: Virtual surgical planning (experimental group)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Clinical experience (control group)
Number of subjects: 50
Study: 32919894

Group type: EXPERIMENTAL
Intervention: 15-minute non-therapeutic hand massage
Number of subjects: 138

Group type: COMPARATOR
Intervention: Rest for 15 minutes (Control)
Number of subjects: 138
Study: 35984434

Group type: EXPERIMENTAL
Intervention: Otoendoscopic tympanoplasty (OP)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Microscope tympanoplasty (MP)
Number of subjects: 76
Study: 35467017

Group type: EXPERIMENTAL
Intervention: Brazil nut supplementation (1 Brazil nut per day for 3 months)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group (no supplementation)
Number of subjects: 37
Study: 33762365

Group type: EXPERIMENTAL
Intervention: CT fractional flow reserve (CTFFR)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Direct ICA without functional test after CTCA
Number of subjects: 140
Study: 32554646

Group type: EXPERIMENTAL
Intervention: Fasting mimicking diet (FMD) plus usual care
Number of subjects: 100

Group type: COMPARATOR
Intervention: Usual care only
Number of subjects: 100
Study: 33883477

Group type: EXPERIMENTAL
Intervention: Physical activity (PA) therapy based on intelligent wearable devices for 8 weeks
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Internet-based modified behavioral activation (BA) therapy for 8 weeks
Number of subjects: 143

Group type: COMPARATOR
Intervention: Routine care (Control group)
Number of subjects: 143
Study: 32880490

Group type: EXPERIMENTAL
Intervention: Readiness Assurance Process (RAP) followed by Immediate Feedback from Faculty-Student Discussion (FSD) and Individual Application Exercises (iAE)
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Individual Readiness Assurance Test (iRAT) and Group Readiness Assurance Test (gRAT)
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Feedback during Faculty-Student Discussion (FSD) after gRAT
Number of subjects: 182
Study: 33074423

Group type: EXPERIMENTAL
Intervention: Retrograde intrarenal surgery (RIRS)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Shock wave lithotripsy (SWL)
Number of subjects: 81
Study: 36357960

Group type: EXPERIMENTAL
Intervention: Relugolix combination therapy (40 mg relugolix, 1 mg estradiol, 0.5 mg norethindrone acetate)
Number of subjects: 477

Group type: EXPERIMENTAL
Intervention: Relugolix combination therapy
Number of subjects: 477
Study: 33621675

Group type: EXPERIMENTAL
Intervention: rTMS over PMdL during planning
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: rTMS over PMdR during planning and execution
Number of subjects: 20
Study: 32237291

Group type: EXPERIMENTAL
Intervention: Fragility Index (FI)
Number of subjects: 0
Study: 35586186

Group type: EXPERIMENTAL
Intervention: Peficitinib 50 mg single dose
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Peficitinib 100 mg single dose
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Peficitinib 150 mg single dose
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Peficitinib multiple doses (50, 100, 150 mg)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Peficitinib multiple doses (higher dose groups)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Peficitinib multiple doses (lower dose groups)
Number of subjects: 36
Study: 34968124

Group type: EXPERIMENTAL
Intervention: Suicide prevention-focused group therapy
Number of subjects: 134
Study: 34458930

Group type: EXPERIMENTAL
Intervention: 3-D/HD imaging technology
Number of subjects: 42

Group type: COMPARATOR
Intervention: 2-D/4K imaging technology
Number of subjects: 42
Study: 32948514

Group type: EXPERIMENTAL
Intervention: Self-injected adrenaline (epinephrine) during food challenge
Number of subjects: 56
Study: 34809904

Group type: EXPERIMENTAL
Intervention: Older age at marriage
Number of subjects: 796

Group type: COMPARATOR
Intervention: Control over decisions
Number of subjects: 796
Study: 32000477

Group type: EXPERIMENTAL
Intervention: Intracuff lidocaine
Number of subjects: 3049

Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine
Number of subjects: 3049

Group type: COMPARATOR
Intervention: Lidocaine jelly
Number of subjects: 3049

Group type: COMPARATOR
Intervention: Lidocaine spray
Number of subjects: 3049
Study: 36130275

Group type: EXPERIMENTAL
Intervention: Brodalumab 210 mg
Number of subjects: 145

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 145
Study: 34436928

Group type: EXPERIMENTAL
Intervention: Veliparib 120 mg twice daily with carboplatin and paclitaxel
Number of subjects: 970

Group type: COMPARATOR
Intervention: Placebo with carboplatin and paclitaxel
Number of subjects: 970

Group type: EXPERIMENTAL
Intervention: Veliparib in LP52-positive population
Number of subjects: 970

Group type: COMPARATOR
Intervention: Placebo in LP52-positive population
Number of subjects: 970

Group type: EXPERIMENTAL
Intervention: Veliparib in LP52-negative population
Number of subjects: 970

Group type: COMPARATOR
Intervention: Placebo in LP52-negative population
Number of subjects: 970

Group type: EXPERIMENTAL
Intervention: Veliparib with chemotherapy
Number of subjects: 970

Group type: COMPARATOR
Intervention: Placebo with chemotherapy
Number of subjects: 970
Study: 36029162

Group type: EXPERIMENTAL
Intervention: Prognostic-efficacy-combination design
Number of subjects: 0

Group type: COMPARATOR
Intervention: Alternative designs
Number of subjects: 0
Study: 33616557

Group type: EXPERIMENTAL
Intervention: ID group (n = 20) with abutment preparations for inlay retainers (proximal box and occlusal extension)
Number of subjects: 30

Group type: COMPARATOR
Intervention: PB group (n = 10) with only proximal box preparations
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study: 32915800

Group type: EXPERIMENTAL
Intervention: PGD symptoms and PGD diagnosis
Number of subjects: 852

Group type: EXPERIMENTAL
Intervention: PGD symptoms and MDE diagnosis
Number of subjects: 852

Group type: EXPERIMENTAL
Intervention: PGD symptoms and no diagnosis
Number of subjects: 852

Group type: COMPARATOR
Intervention: No PGD symptoms and no diagnosis (integrated grief)
Number of subjects: 852

Group type: EXPERIMENTAL
Intervention: Gender of the bereaved (male vs female)
Number of subjects: 852
Study: 36221155

Group type: EXPERIMENTAL
Intervention: Subfascial TQL block
Number of subjects: 80
Study: 33854404

Group type: COMPARATOR
Intervention: CHD group
Number of subjects: 49

Group type: COMPARATOR
Intervention: HC group
Number of subjects: 49

Group type: COMPARATOR
Intervention: CHD group and HC group
Number of subjects: 49
Study: 32480364

Group type: EXPERIMENTAL
Intervention: Machine learning-based prediction
Number of subjects: 151
Study: 35982348

Group type: EXPERIMENTAL
Intervention: Fixed appliances
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Removable appliances
Number of subjects: 135

Group type: COMPARATOR
Intervention: Control (teeth without trauma)
Number of subjects: 135
Study: 34120912

Group type: EXPERIMENTAL
Intervention: Edasalonexent (100 mg/kg/day)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 131
Study: 36255383

Group type: EXPERIMENTAL
Intervention: Baseline ACPA IgA
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Baseline ACPA IgG
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: ACPA IgA and IgG levels
Number of subjects: 97
Study: 32275468

Group type: COMPARATOR
Intervention: Nivolumab
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Nivolumab plus Ipilimumab
Number of subjects: 100
Study: 33272980

Group type: EXPERIMENTAL
Intervention: Low-dose tamoxifen (5 mg/day)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 32131824

Group type: EXPERIMENTAL
Intervention: Internal facilitators (IFs) with strong project management, team/process, and influencing/negotiating skills
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Prior experience in project management and mental health background
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Personal characteristics of IFs (e.g., flexible, assertive)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Clear delineation of EF/IF roles
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Shift of facilitation responsibilities to IFs
Number of subjects: 9
Study: 35853716

Group type: EXPERIMENTAL
Intervention: Standard urine chemistries
Number of subjects: 418

Group type: EXPERIMENTAL
Intervention: NMR urine metabolites
Number of subjects: 418

Group type: EXPERIMENTAL
Intervention: Combined model using urine chemistries and NMR-quantified metabolites
Number of subjects: 418
Study: 33524985

Group type: EXPERIMENTAL
Intervention: OCT-guided percutaneous coronary intervention with implantation of a magnesium sirolimus-eluting Magmaris scaffold
Number of subjects: 0

Group type: COMPARATOR
Intervention: Angiography-guided percutaneous coronary intervention with implantation of a magnesium sirolimus-eluting Magmaris scaffold
Number of subjects: 0
Study: 35882511

Group type: EXPERIMENTAL
Intervention: Ninjin'yoeito (NYT)
Number of subjects: 1066

Group type: COMPARATOR
Intervention: Oral iron preparation
Number of subjects: 1066
Study: 34289884

Group type: EXPERIMENTAL
Intervention: Twice-weekly KBA training (n = 40)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Thrice-weekly KBA training (n = 40)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Conventional physiotherapy (n = 40)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: All groups (including KBA and control)
Number of subjects: 120
Study: 35467561

Group type: EXPERIMENTAL
Intervention: At-home blood pressure measurement protocol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nourish trial intervention (Dietary Approaches to Stop Hypertension)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Remote visits due to COVID-19
Number of subjects: 0
Study: 32402555

Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab 0.5 mg monthly
Number of subjects: 1097

Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab 0.5 mg pro re nata (PRN) after 3 loading doses
Number of subjects: 1097

Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab 2.0 mg monthly
Number of subjects: 1097

Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab 2.0 mg PRN
Number of subjects: 1097

Group type: EXPERIMENTAL
Intervention: Baseline risk factors for MA
Number of subjects: 1097
Study: 35710044

Group type: EXPERIMENTAL
Intervention: Optimal combos (low-calorie default items)
Number of subjects: 636

Group type: COMPARATOR
Intervention: Traditional combos (high-calorie default items)
Number of subjects: 636

Group type: COMPARATOR
Intervention: Choice combos (create-your-own combo)
Number of subjects: 636

Group type: COMPARATOR
Intervention: Photos (visual cues)
Number of subjects: 636
Study: 34162645

Group type: EXPERIMENTAL
Intervention: 12-week open-label placebo treatment
Number of subjects: 0
Study: 32216840

Group type: EXPERIMENTAL
Intervention: In-home intervention program over 4 months consisting of six home visits and two telephone contacts with a rehabilitation professional.
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standard care in the municipalities (control group).
Number of subjects: 120
Study: 32213291

Group type: EXPERIMENTAL
Intervention: Quetiapine 12.5 mg every 12 hours
Number of subjects: 71

Group type: COMPARATOR
Intervention: No pharmacologic prophylaxis
Number of subjects: 71
Study: 32311001

Group type: EXPERIMENTAL
Intervention: Relative performance information feedback
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 34166959

Group type: EXPERIMENTAL
Intervention: Pharmacist-led educational intervention on inhalation technique education via demonstration and repetition
Number of subjects: 201
Study: 32010994

Group type: EXPERIMENTAL
Intervention: New predictive equations for estimating resting energy expenditure (REE)
Number of subjects: 270

Group type: COMPARATOR
Intervention: Commonly used equations for estimating REE
Number of subjects: 270
Study: 35834340

Group type: EXPERIMENTAL
Intervention: Bicycle ergometer exercise at the rehabilitation center under medical staff monitoring
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Home-based exercise (HBE) by dosed walking
Number of subjects: 67

Group type: COMPARATOR
Intervention: Both groups (Bicycle ergometer and HBE)
Number of subjects: 67
Study: 33634858

Group type: EXPERIMENTAL
Intervention: Neoadjuvant therapy (NAT) with imatinib, median duration 6.3 months
Number of subjects: 16308

Group type: EXPERIMENTAL
Intervention: Neoadjuvant therapy (NAT)
Number of subjects: 16308

Group type: COMPARATOR
Intervention: Upfront resection (UR)
Number of subjects: 16308

Group type: COMPARATOR
Intervention: Neoadjuvant therapy (NAT) vs Upfront resection (UR)
Number of subjects: 16308
Study: 33142500

Group type: EXPERIMENTAL
Intervention: 8% corn resistant starch (RS)
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: 12% corn resistant starch (RS)
Number of subjects: 320

Group type: COMPARATOR
Intervention: NC and CS (control groups)
Number of subjects: 320
Study: 34906371

Group type: EXPERIMENTAL
Intervention: Minimally invasive distal pancreatectomy
Number of subjects: 247

Group type: COMPARATOR
Intervention: Open distal pancreatectomy
Number of subjects: 247
Study: 34221852

Group type: EXPERIMENTAL
Intervention: Additional information about benefits and harms of cervical cancer screening
Number of subjects: 2144

Group type: EXPERIMENTAL
Intervention: Prior Pap-test
Number of subjects: 2144

Group type: EXPERIMENTAL
Intervention: Lower income
Number of subjects: 2144
Study: 36293748

Group type: EXPERIMENTAL
Intervention: ANZANSI intervention (combination of family economic empowerment and multiple family group family strengthening)
Number of subjects: 20
Study: 33515087

Group type: EXPERIMENTAL
Intervention: Radiological reports made with clinical information
Number of subjects: 410

Group type: COMPARATOR
Intervention: Radiological reports made without clinical information
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: Clinical management based on radiological diagnoses with clinical information
Number of subjects: 410

Group type: COMPARATOR
Intervention: Clinical management based on radiological diagnoses without clinical information
Number of subjects: 410
Study: 34431828

Group type: EXPERIMENTAL
Intervention: 12-month lifestyle intervention (aerobic training sessions combined with resistance training)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 98
Study: 34622750

Group type: EXPERIMENTAL
Intervention: Dietary supplement of 4% ARA
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Dietary supplement of ARA (various levels)
Number of subjects: 25
Study: 35481708

Group type: EXPERIMENTAL
Intervention: Center-based early childhood development intervention including individual parenting training, group activities, and open play space in village parenting centers.
Number of subjects: 1664

Group type: EXPERIMENTAL
Intervention: Subgroup analyses by caregiver socioeconomic status and identity (mother vs. grandmother).
Number of subjects: 1664
Study: 34960037

Group type: EXPERIMENTAL
Intervention: Synbiotic supplementation
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study: 36084566

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 244

Group type: COMPARATOR
Intervention: Enoxaparin
Number of subjects: 244
Study: 33453192

Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy combined with oral medication and exercise
Number of subjects: 32

Group type: COMPARATOR
Intervention: Sham extracorporeal shock wave therapy combined with oral medication and exercise
Number of subjects: 32
Study: 35107401

Group type: EXPERIMENTAL
Intervention: Humor-based contraception education (one-time education of 45-60 minutes)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Standard contraception education (one-time education of 45-60 minutes)
Number of subjects: 88
Study: 34033205

Group type: EXPERIMENTAL
Intervention: Parents under Pressure (PuP) programme
Number of subjects: 100

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 100
Study: 35351353

Group type: EXPERIMENTAL
Intervention: Online self-help using cognitive-behavioral therapy and positive psychology principles (n = 301)
Number of subjects: 585

Group type: COMPARATOR
Intervention: Referral to usual care (n = 284)
Number of subjects: 585
Study: 34196269

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy plus standardised medical care
Number of subjects: 368

Group type: COMPARATOR
Intervention: Standardised medical care alone
Number of subjects: 368
Study: 32883262

Group type: EXPERIMENTAL
Intervention: Unmet need for family planning services
Number of subjects: 535

Group type: EXPERIMENTAL
Intervention: Spacing methods
Number of subjects: 535

Group type: EXPERIMENTAL
Intervention: Limiting methods
Number of subjects: 535

Group type: EXPERIMENTAL
Intervention: Determinants of unmet need
Number of subjects: 535
Study: 34609052

Group type: EXPERIMENTAL
Intervention: Pretraining of basic psycho-motor skills (Navigation Training level 2 and Bimanual Training level 3)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Procedure-specific modules (Posterior Hyaloid level 3 and ILM Peeling level 3)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: ILM peeling level 3 starting score
Number of subjects: 68
Study: 32824061

Group type: EXPERIMENTAL
Intervention: Mindfulness treatment (flow meditation)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 51
Study: 33200213

Group type: COMPARATOR
Intervention: PVI alone
Number of subjects: 512

Group type: EXPERIMENTAL
Intervention: PVI plus CFAE and/or linear ablation
Number of subjects: 512
Study: 32779416

Group type: EXPERIMENTAL
Intervention: Antibiotics + bee products
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Bee products
Number of subjects: 104

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104

Group type: COMPARATOR
Intervention: Antibiotics
Number of subjects: 104
Study: 33671743

Group type: EXPERIMENTAL
Intervention: Didactic video based on the mental health Gap Action Programme (mhGAP)
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: Service user video about living with mental illness
Number of subjects: 307

Group type: COMPARATOR
Intervention: Control condition with no videos
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: Service user video describing depression and psychosis
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: Didactic video addressing depression and psychosis
Number of subjects: 307
Study: 33762229

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 12200

Group type: COMPARATOR
Intervention: Low-molecular-weight heparin (LMWH)
Number of subjects: 12200
Study: 32025843

Group type: EXPERIMENTAL
Intervention: Clearfast® beverage
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Gatorade Thirst Quencher® beverage
Number of subjects: 47

Group type: COMPARATOR
Intervention: Fasting control
Number of subjects: 47
Study: 35266127

Group type: EXPERIMENTAL
Intervention: Intensive, multidisciplinary transitional care (TC) services
Number of subjects: 653

Group type: COMPARATOR
Intervention: Routine coordination of post‐discharge care (RC)
Number of subjects: 653
Study: 32538865

Group type: EXPERIMENTAL
Intervention: Weekly ParkinSong
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Monthly ParkinSong
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: ParkinSong participants
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Caregivers attending ParkinSong
Number of subjects: 75

Group type: COMPARATOR
Intervention: Monthly control
Number of subjects: 75

Group type: COMPARATOR
Intervention: Weekly control
Number of subjects: 75
Study: 34453873

Group type: EXPERIMENTAL
Intervention: 10% hydrogen peroxide (HP) gel with prefilled trays (PT) for 30 minutes
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 10% hydrogen peroxide (HP) gel with customized trays (CT) for 30 minutes
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 10% carbamide peroxide (CP) gel with customized trays (CT) for 2 hours
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 10% carbamide peroxide (CP) gel with customized trays (CT) for 8 hours
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional nightguard vital bleaching (10% CP)
Number of subjects: 60